Received Mar 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | PO / MO |
The patient took first three doses of the Vivotif vaccine correctly and did not take the last one for three days; Case reference number US-BN-2024-002914 is a spontaneous case initially received from other healthcare professional via Med Communication (reference number: USBAV24-3360) on 19-Dec-2024 and concerns a patient of unknown age and gender. The patient's medical history and concomitant medication details were not provided. On an unspecified dates, the patient took first, second and third dose of Vivotif (batch number: unknown), at a dose of one capsule, orally, for an unknown indication. As reported, the patient took first three doses of the Vivotif vaccine correctly and did not take the last one for three days (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif vaccine. Non-significant follow-up was downloaded from VAERS on 09-May-2025 included new reference number. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20241219-636bd6 to US-BAVARIAN NORDIC A/S-US-BN-2024-002914, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A patient of unknown age and gender did not take the last dose of Vivotif for three days which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse events due to Rabipur. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A patient of unknown age and gender did not take the last dose of Vivotif for three days which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse events due to Rabipur. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None